XNW27011

XNW27011 is an antibody-drug conjugate developed by Astellas Pharma Global Development. Its target is Claudin 18.2 (the sponsor names Claudin 18.2 (CLDN18.2)). The sponsor states: XNW27011 is an antibody-drug conjugate targeting Claudin 18.2, a tight-junction transmembrane protein, carrying the topoisomerase I inhibitor payload YL0010014, given intravenously every three weeks. ClinicalTrials.gov describes the intervention as: Eligible patient(s) in each dose cohort will receive the assigned XNW27011 dose administration every 3 weeks (Q3W, cycle) until intolerable toxicity, progression of the disease without clinical benefit, or withdrawal of informed consent. An. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in pancreatic ductal adenocarcinoma, non-small-cell lung cancer, ovarian cancer, colorectal cancer and biliary tract cancer. The largest, NCT06792435, plans to enrol 240 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.